Kura Oncology, Inc. $KURA Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP raised its position in Kura Oncology, Inc. (NASDAQ:KURA) by 130.1% during the 1st quarter, HoldingsChannel.com reports. The firm owned 89,303 shares of the company’s stock after acquiring an additional 50,498 shares during the period. Quantinno Capital Management LP’s holdings in Kura Oncology were worth $726,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in KURA. IFP Advisors Inc raised its position in shares of Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares during the period. Allworth Financial LP raised its position in Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after purchasing an additional 1,553 shares during the period. EverSource Wealth Advisors LLC raised its position in Kura Oncology by 49.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after purchasing an additional 1,888 shares during the period. Insigneo Advisory Services LLC acquired a new position in shares of Kura Oncology in the 4th quarter valued at $105,000. Finally, LPL Financial LLC purchased a new position in shares of Kura Oncology during the 4th quarter worth $105,000.

Insider Buying and Selling at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Troy Edward Wilson bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were purchased at an average price of $11.12 per share, for a total transaction of $1,112,000.00. Following the completion of the purchase, the chief executive officer directly owned 379,194 shares of the company’s stock, valued at approximately $4,216,637.28. This trade represents a 35.82% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 7.60% of the company’s stock.

Kura Oncology Trading Up 9.3%

Shares of KURA stock opened at $12.33 on Wednesday. Kura Oncology, Inc. has a fifty-two week low of $6.95 and a fifty-two week high of $12.85. The company has a 50 day moving average price of $10.34 and a 200 day moving average price of $9.39. The stock has a market capitalization of $1.09 billion, a P/E ratio of -3.66 and a beta of 0.38. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Equities research analysts predict that Kura Oncology, Inc. will post -3.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on KURA. Oppenheimer set a $24.00 price objective on shares of Kura Oncology in a report on Thursday, May 28th. Citizens Jmp restated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a report on Monday, June 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Wedbush boosted their target price on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.62.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.